drugset / Trial / NCT04544111
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.
Timeline
- Start
- 2020-09-02
- Primary completion
- 2026-09-02
- Completion
- 2026-09-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | 150 mg | Oral |
| Subject | Spartalizumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Trametinib | Small molecule | 2 mg | Oral |